Brentuximab vedotin is approved by FDA in combination with chemotherapy for pediatric patients with classical Hodgkin lymphoma

Brentuximab vedotin

Share This Post

November 2022: The combination of doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide with brentuximab vedotin (Adcetris, Seagen, Inc.) has been approved by the Food and Drug Administration for use in children and young adults with high-risk classical Hodgkin lymphoma who have not received treatment in the past (cHL). This is brentuximab vedotin’s first paediatric approval.

A randomised, open-label, actively controlled trial was used to assess effectiveness. Stage IIB with bulk illness in Ann Arbor, Stage IIIB, Stage IVA, and Stage IVB were all classified as high risk. Brentuximab vedotin plus doxorubicin (A), vincristine (V), etoposide (E), prednisone (P), and cyclophosphamide (C) [brentuximab vedotin + AVEPC] was given to 300 patients, while A+bleomycin (B)+V+E+P+C [ABVE-PC] was given to 300 patients. Each treatment arm’s patients could have had up to 5 cycles of the following:

Prednisone 20 mg/m2 BID (days 1-7), cyclophosphamide 600 mg/m2 (days 1 and 2), doxorubicin 25 mg/m2 (days 1 and 2), vincristine 1.4 mg/m2 (days 1 and 8), etoposide 125 mg/m2 (days 1-3), and brentuximab vedotin 1.8 mg/kg over 30 minutes (day (days 1 and 2).
Event-free survival (EFS), which is the time from randomization to the earliest of disease progression or recurrence, second malignancy, or death from any cause, served as the primary effectiveness outcome measure. In neither arm was the median EFS attained. With a comparable hazard ratio of 0.41 (95% CI: 0.25, 0.67; p=0.0002), there were 52 occurrences (17%) in the ABVE-PC arm and 23 events (8%) in the brentuximab vedotin + AVEPC arm.

In paediatric patients receiving brentuximab vedotin in combination with AVEPC, neutropenia, anaemia, thrombocytopenia, febrile neutropenia, stomatitis, and infection were the most frequent Grade 3 adverse events (5%).

For children 2 years of age and older, the suggested brentuximab vedotin dose is 1.8 mg/kg up to 180 mg in conjunction with AVEPC every 3 weeks for a maximum of 5 doses.

View full prescribing information for Adcetris.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

After amazing growth of CAR T-Cell therapy what's next
CAR T-Cell therapy

After amazing growth of CAR T-Cell therapy: what’s next?

CAR T-cell therapy has rapidly transformed cancer treatment by reprogramming a patient’s T-cells to attack cancer cells, demonstrating remarkable success in hematologic cancers. Advances in genetic engineering, regulatory support, and investment are driving further expansion. Researchers are now tackling the challenges of applying this therapy to solid tumors, aiming to enhance efficacy and accessibility, marking a new era in personalized cancer therapy and immunotherapy.

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS
Cancer

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate, a groundbreaking treatment, has recently received approval from the US Food and Drug Administration (FDA) for pediatric patients, marking a significant milestone in pediatric oncology. This approval represents a beacon of hope for children battling neuroendocrine tumors (NETs), a rare but challenging form of cancer that often proves resistant to conventional therapies.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy